Zimmerman, M., Gottsater, A
GLP-1 receptor agonists are intended for adults with obesity (BMI 30) or those who are overweight (BMI 27) with associated metabolic conditions such as hypertension, dyslipidaemia, or type 2 diabetes
The bank's researchers said the anti-obesity drug market could grow to $100 billion by that time
Even if you do not meet the strict criteria for traditional maximum-dose weight loss, you may still be an excellent candidate for our metabolic support or microdosing options
Patients should be counselled that allulose is not a substitute for prescribed medication and should not be viewed as enhancing drug efficacy without evidence
Third, significant variations in the duration of follow-up of the included studies may have impacted the findings related to colorectal cancer risk